Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the ...

Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury ...

Key Takeaways Pfizer said it will discontinue development of oral daily weight-loss treatment danuglipron.A Phase 3 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

Pfizer said it would stop studying the pill after a participant in one of its trials experienced a drug-induced liver injury.

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

Liver injury is an independent risk factor for multiple organ dysfunction and high mortality in patients with sepsis. However, the pathological mechanisms and therapeutic strategies for ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...